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Available online 29 July 2017Latently human immunodeficiency virus (HIV)-infected cells are transcriptionally quiescent and invisible to
clearance by the immune system. To demonstrate that the latency reversing agent vorinostat (VOR) induces a
windowof vulnerability in the latentHIV reservoir, defined as the triggering of viral antigen production sufficient
in quantity and duration to allow for recognition and clearance of persisting infection, we developed a latency
clearance assay (LCA). The LCA is a quantitative viral outgrowth assay (QVOA) that includes the addition of im-
mune effectors capable of clearing cells expressing viral antigen. Here we show a reduction in the recovery of
replication-competent virus from VOR exposed resting CD4 T cells following addition of immune effectors for a
discrete period. Take homemessage: VOR exposure leads to sufficient production of viral protein on the cell sur-
face, creating a window of vulnerability within this latent reservoir in antiretroviral therapy (ART)-suppressed
HIV-infected individuals that allows the clearance of latently infected cells by an array of effector mechanisms.Chapel H
).
. This is a©2017 TheAuthors. Publishedby Elsevier B.V. This is an open access article under the CCBY-NC-ND license
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Immune effector1. Introduction
Antiretroviral therapy (ART) is highly successful at suppressing viral
replication in HIV-infected individuals, yet viremia returns following
the cessation of therapy due to the persistence of replication-
competent human immunodeficiency virus (HIV) in a quiescent, latent
reservoir (Chun et al., 1997, 2010; Finzi et al., 1999). Currently, one of
themost well-developed strategies for eradication of the latent HIV res-
ervoir hinges on first inducing viral antigen expression through expo-
sure to a latency reversing agent, allowing for detection by immune
effector cells, followed by subsequent clearance of the now vulnerable
infected cells by the immune response or other therapeutics (Archin
and Margolis, 2014).
Inhibitors of histone deacetylases (HDACis) target the formation of a
repressive chromatin environment that inhibits long terminal repeat
(LTR) expression and viral production, andmay be useful in eradication
strategies. A significant increase in cell-associated ribonucleic acid
(RNA) production following in vivo administration of HDAC inhibitors,ill, Chapel Hill, United
n open access article underincluding vorinostat (VOR), to ART-suppressed individuals has been
shown in initial proof of concept studies (Archin et al., 2014; Sogaard
et al., 2015; Elliott et al., 2014; Rasmussen et al., 2014; Archin et al.,
2012). Additional studies have shown that VOR leads to induction of ge-
netically diverse cell-associated RNA that is similar to the diversity
found in corresponding deoxyribonucleic acid (DNA) sequences, sug-
gesting activation of transcription fromabroad representation of persis-
tent HIV-1 proviruses (Barton et al., 2016).
However, measurements of cell-associated HIV RNA expression are
limited in several respects. Such RNA measurements following ex vivo
stimulation overestimate the frequency of latent but replication-
competent virus (Eriksson et al., 2013). Themajority of HIV RNA detect-
ed in such assays encode mutations or deletions that render them un-
able to produce infectious virions, and are therefore clinically
irrelevant from the standpoint of eradication efforts (Barton et al.,
2016; Bruner et al., 2016; Ho et al., 2013). Cell-associated HIV RNA is
thus an imperfect surrogate for infectious virion production.
Further, if immunotherapies are to be used to clear persistent infec-
tion then effective latency reversal must be defined as the presentation
of viral protein or antigen by the latently infected cell in a sufficient
quantity and for a sufficient length of time for cells harboring replication
competent virus to be recognized and cleared. As directmeasurement ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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reversal is not achievable with currently available assays, we have de-
veloped the latency clearance assay (LCA) as an ex vivo assay to validate
that this goal, the opening of a “window of vulnerability” in the persis-
tent, latent reservoir of HIV infection, can be achieved by a selected
intervention.
We have described the LCA in earlier demonstrations of the in-vitro
efficacy of various immunotherapeutic approaches (Sung et al., 2015a,
b). Previously we have shown that over a prolonged co-culture period
of 15 days these interventions led to a reduction in the recovery of rep-
lication competent virus, we cannot completely exclude the possibility
that inhibition of virus spread contributed to the antiviral effect ob-
served. We therefore modified the LCA to include the addition of
antiretrovirals and the removal of CD8 T cells from co-culture following
a discrete period of time, and now unequivocally demonstrate that VOR
produces a window of vulnerability within the latent HIV reservoir. We
usedmultiple effectormechanisms that detect and clear distinctHIV an-
tigens, including autologous CD8 T cells redirected to infected targets
expressing HIV-1 Env on the cell surface via bispecific HIV × CD3
DART®molecules (Sung et al., 2015b, Sloan et al., 2015), and autologous
HIV-specific T cells that had been expanded ex vivo (HXTCs) (Sung
et al., 2015a; Lam et al., 2015), and target HIV-1 peptides presented by
major histocompatibility complexes (MHC) on the cell surface. We
show that after VOR induction of viral antigen expression from the au-
tologous resting CD4 T cells of ART suppressed, HIV infected individuals
can be detected and cleared by effectors. These approaches are now en-
tering clinical proof-of-concept studies.
2. Materials and Methods
2.1. Participants
This study was reviewed and approved by the University of North
Carolina at Chapel Hill Biomedical Institutional Review Board, and writ-
ten informed consent obtained from each participant. The study was
performed in accordance with the Declaration of Helsinki. Participants
were drawn from cohorts of HIV-infected individuals on stable, sup-
pressive ART with undetectable plasma viremia (b50 copies/ml) for at
least 24 months.
2.2. Latency Clearance Assay (LCA)
The LCA was performed as previously described (Sung et al., 2015a,
b) with the following modifications. Briefly, resting CD4 T-cells were
isolated from a leukapheresis product by negative selection and ex-
posed to VOR (335n; gift of Merck Research Laboratories) at a concen-
tration of 5 million/ml in the presence of the antiretrovirals abacavir
(4 μM) and raltegravir (1 μM). After 6 h, cells were extensively washed,
and effectors added at an effector:target ratio of 1:10. Antiretrovirals
were again added, and cells were co-cultured at a concentration of 5
million resting CD4 T cells/ml. After 24 h, cells were extensively washed
and depleted of CD8 T cells via three serial magnetic selections
(StemCell Technologies, Vancouver, BC). Remaining CD4 T cells were
recounted, then plated in 16 to 48 replicate wells at 0.25 to 1 million
cells/well (depending on cell availability and reservoir size) and cul-
tured with allogeneic CD8-depleted peripheral blood mononuclear
cells (PBMCs) from an HIV-negative donor to amplify any residual
virus. The presence of HIV Gag p24 antigen was measured on day 15,
and confirmed on day 19 for each well by ELISA (ABL, Rockville, MD).
Each LCA was performed at an independent time point.
2.3. Reagents and Generation of HXTCs
HXTCs were generated as previously described (Sung et al., 2015a;
Lam et al., 2015). Briefly monocytes were isolated from peripheral
blood mononuclear cells (PBMCs) by plastic adherence. Dendritic cellswere generated using standard cytokine cocktails of IL-4, GM-CSF, IL-
1β, IL-6, and TNF-α. Non-adherent PBMCs were cryopreserved and
thawed upon completion of dendritic cell generation. PBMCswere stim-
ulated with irradiated autologous dendritic cells pulsed with Gag, Pol
andNef peptide pools in the presence of IL7, IL-15, and IL12 for an initial
stimulation. Cells were then co-cultured with autologous PHA-treated
blasts pulsed with Gag, Pol and Nef peptide pools in the presence of
IL-15 and IL-2 for a second and IL-2 for a third round of stimulation.
HIV peptide pools comprised 150, 15-mer peptides providing broad
coverage of Gag p24, Pol, and Nef across clades (JPT Peptide Technolo-
gies). Irradiated K562 cells modified to overexpress the co-stimulatory
molecules CD80, CD83, CD86 and 4-1BBL were used in the third stimu-
lation. Cells were cultured in the presence of indinavir and raltegravir
(Merck, Kenilworth NJ) to prevent replication of HIV.
HIV DARTmolecules (provided byMacrogenics) were used as previ-
ously described (Sung et al., 2015b; Sloan et al., 2015).
2.4. HIV-specific Responses
IFNγ ELIspot assays were used to assess for the presence of HIV-
specific responses in PBMCs from participants. Cryopreserved PBMCs
obtained from the same leukapheresis procedure that provided PBMCs
for the LCA were thawed and resting overnight for 16–24 h in RPMI
with 10% FBS, 5% Pen/Strep. Cells were then harvested, recounted, and
plated at 4 × 105 cells/well in triplicate and stimulated with peptide
pools at a final concentration of 2 μg/ml for 18–20 h. For each assay,
four negative control wells (no peptide, ‘Mock’) and two positive con-
trol wells (PHA at a final concentration of 10 μg/ml, Sigma-Aldrich)
were included. A threshold of 4× Mock and N50 SFU/106 was used to
determine positive responses, as previously reported by others
(Goonetilleke et al., 2006, 2009).
Clade B consensus peptide pools for Gag, Nef and Pol were obtained
from NIH AIDs Reagent program, Division of AIDS, NIAID, NIH.
2.5. Statistical Analysis
Statistical comparisons between groups were analyzed using the
Kruskall-Wallis or Friedman nonparametric test with Dunn's posttest
correction for multiple comparisons. Fisher's exact test was used for in-
dividual participants. p b 0.05 was considered significant.
3. Results
3.1. Participants
The 15 participants studied were all suppressed for at least 2 years,
with a median duration of suppression of 5.5 years (range 2–8.5) and
awide range of latent reservoir sizes asmeasured by the standard quan-
titative viral outgrowth assay followingmaximal mitogenic stimulation
(QVOA;median0.76, range 0.04 to 2.30 infectious units permillion rest-
ing CD4 T cells; Table 1), reflecting the spectrum of chronic HIV-1
infection.
3.2. VOR Induces MHC Presentation of HIV Peptides Detectable by CD8 T
Cells
An LCAwas performed for each individual participant independent-
ly, as shown in Fig. 1. Following a 6 h exposure of resting CD4 T cells to
335 nM of VOR, chosen to mimic physiologically achievable levels
in vivo following both single and multiple doses of vorinostat, which
maintain similar PK parameters (Archin et al., 2012; Archin et al.,
2014, 2017), the frequency of cultures in which p24 was detected fol-
lowing VOR exposure is significantly greater than that in cultures treat-
ed with only 2 U/ml IL2 (no stimulation; Fig. 2A). As measured by a
reduction in the recovery of virus from latently infected cells, VOR in-
duced the expression of HIV to an extent sufficient to allow clearance
Table 1
Demographics of participants and frequency of latent infection.
Participant Symbol Nadir CD4 count Current CD4 count Viremia suppression (years) IUPMa Number cells assayed with VOR/group (million)
CP1 ▲ 508 960 3.5 0.04 34
CP2 ■ 480 766 5.5 0.05 24
CP3 ● 49 610 8 0.10 12
CP4 ♦ 499 706 2 0.28 12
CP5 ▼ 277 615 7.5 0.37 24
CP6 N.A. 704 8.5 0.37 8
CP7 ◊ 373 391 3 0.38 10
CP8 195 886 8.5 0.76 30
CP9 338 857 4 0.891 9
CP10 81 619 6.5 0.97 12
CP11 u/k 491 8 1.05 12
CP12 78 557 8.5 1.15 9
CP13 604 1302 2 1.17 24
CP14 ○ 243 439 4.5 1.67 12
CP15 □ 526 850 2.5 2.30 18
CP = Participant treated in chronic, progressive HIV infection.
a Infectious units per million resting CD4 cells (IUPM) determined by Quantitative Outgrowth Assay (QVOA (Lam and Bollard, 2013)).
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CD8+ T cells at an effector to target ratio of 1:1 led to a significant re-
duction in the percentage of p24+ wells recovered, with complete ab-
lation of viral recovery in 7 of the 9 participants studied at this ratio (Fig.
2A, p= 0.001 by Kruskal-Wallis testwith Dunn's posttest correction for
multiple comparisons). This effect was dependent on CD8 T cell fre-
quency; while there was a reduction in the percentage of p24+ wells
recovered with the addition of autologous CD8 T cells at an
effector:target (E:T) ratio of 1:10, this did not reach significance (Fig.
2A).
TheQVOA is designed to detect the presence of absence of HIV-1 p24
within each well as a qualitative measure, rather than as a quantitative
measure within each well (Archin et al., 2008). Similar to what we have
seen with the traditional QVOAwhen PHA or VOR are used as the stim-
ulus, in which the presence of reactivated virus in a well leads to robust
viral replication and spread over the two week period that exceeds the
quantifiable limits of the assay, positivewells in the LCAwere also aboveFig. 1. Latency clearancthe limit of quantification of the assay. This was true for all conditions
tested; although the frequency of positive wells differed, the ability of
HIV to spread within wells that were positive, as reflected by the high
quantity of p24 produced, was unaffected. This is what would be ex-
pected from an effect that takes place after virus reactivation but before
virus spread.
A potential approach to increasing the frequency of effective HIV-1
specific T cell immune responses is through the use of adoptive T cell
therapy with ex-vivo expanded HIV-1 specific T cells (Lam et al.,
2015; Sung et al., 2015a; Lam and Bollard, 2013). HIV-specific ex vivo
expanded T cells (HXTCs; (Sung et al., 2015a)) are currently under clin-
ical evaluation in ART suppressed, HIV-infected individuals
(clinicaltrials.gov NCT registration number pending). HXTCs were
used as effectors in the LCA, to illustrate the relevance of VOR activity
in the context of amore potent antiviral response (Fig. 2B). In three par-
ticipants with an incomplete reduction in virus recovery with CD8 T-
cells at an E:T ratio of 1:10 (participants CP1, CP6, and CP9), the additione assay overview.
Fig. 2. VOR induces antigen detectable via TCR:MHC interactions. Resting CD4 T cells are
exposed to 6 h of 335 nM of VOR, and then the LCA is performed (A) with or without
unmodified, autologous CD8 cells at an E:T ratio of 1:10 or 1:1, (B) with unmodified,
autologous CD8 cells or ex- vivo expanded HIV specific T cells (HXTC) at an E:T ratio of
1:10, or (C) with or without effectors in the presence or absence of MHC-I blockade (C).
Results are shown as % of plated wells HIV Gag p24 positive ((#positive wells × 100) /
total #plated wells). *Indicates p b 0.01 by Kruskal-Wallis with Dunn's posttest
correction for multiple comparisons. **Indicates p b 0.05 by Fishers exact test compared
to cultures without CD8 cells.
Fig. 3. HIV-specific responses of participants. PBMCs from 13 of the participants who had
sufficient cells cryopreserved and stored for analysis from the same leukapheresis product
used in the latency clearance assaywere thawed and resting overnight. Cellswere counted
and plated in triplicate at 400 k cells/well on an IFNγ coated plate and stimulated with 2
μg/ml of the indicated Clade B consensus peptide pool (Gag, Pol, or Nef or media alone
for the Mock control). After 16 h of culture, Elispot plates were washed and incubated
with secondary anti-IFNγ antibody for 24 h, after which plates were developed and
spots counted. Results are shown as SFU per million PBMCs. A threshold of N4× Mock
and N50 SFU/106 were considered positive (dotted line). Detectable but negative
responses by this threshold are shaded in gray.
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recovery (Fig. 2B). In contrast, no reduction in virus recovery was seen
with the addition of cells expanded ex-vivo against irrelevant, Flu-
EBV-CMV antigens (irr (EBV)XTC) in the participant CP1, for whom an
irr (EBV)XTC line made (same number of positive wells in the control
with no CD8 T cells added and with irr (EBV)XTC added), indicating
the observed reduction with HXTCs was HIV-specific.
The overall observed reduction in virus recovery by HXTCs at an E:T
of 1:10, and CD8s at the E:T ratio of 1:1, is thus most likely reflective of
induction of antigen detectable through a TCR:MHC interaction follow-
ingVORexposure. Demonstrating that this antiviral effectwas the result
of an HIV-specific response, MHC I blockade led to a substantial block of
HXTC and CD8 mediated reduction in virus recovery (Fig. 2C). The ob-
served reduction in virus recovery was not completely reversed, how-
ever, which could either be from incomplete blockade of MHC I given
the high concentrations of cells used in the assay, the presence of
MHC IImediated activity, or partial contribution of non-specific antiviral
effects. However, the majority of the activity was reversed, confirming
that the observed reduction in virus recovery was dependent on TCR:
MHC interactions, at least in the 4 participants with sufficient cells to
test at this condition.3.3. CD8 T Cells From all Participants Show Detectable HIV-specific
Responses
Frozen PBMCs from 13 participants were available to evaluate for
the presence of HIV-specific responses, as measured by IFNγ Elispot. A
conservative threshold for positive responses as N50 SFU/106 PBMCs
and N4× the Mock control was employed, based on prior literature
(Goonetilleke et al., 2009; Goonetilleke et al., 2006; Liu et al., 2013).
Using this criteria, PBMCs from all 13 participants demonstrated re-
sponses to at least one of the three tested peptide pools (Gag, Nef, or
Pol) (Fig. 3). Negative responses were only seen to the Nef peptide
pool (in two participants); all 13 participants demonstrated a positive
detectable response to theGag and Pol peptide pools, perhaps reflecting
the more conserved nature of these proteins. A range of magnitudes of
positive responses were observed across participants: 95 to 942 SFU/
106 PBMCs to the Gag peptide pool, 59.5 to 807 SFU/106 PBMCs to the
Nef peptide pool, and 62.8 to 1279 SFU/106 PBMCs.
3.4. VOR Induces Cell Surface Expression of Env, Detectable by DART
Molecules
We also utilized HIV DART molecules (Sung et al., 2015b) to assess
the LCA in the context of an alternative clearance approach. HIV DART
molecules are antibody-based bispecific proteins that redirect polyclon-
al T cells to HIV-1 Env-expressing cells.We tested DARTmolecules with
anHIV-specific domain that is based on the variable region of the broad-
ly binding antibodies 7B2 (directed towards a gp41 epitope) or A32 (di-
rected towards a CD4 induced gp120 epitope) (Acharya et al., 2014;
Pincus et al., 2003). Thus, CD3+ effector cells are recruited to bind
and kill HIV Env-expressing cells regardless of underlying TCR specific-
ity. We have previously shown that HIV DART molecules are capable of
redirecting T cells against autologous reservoir virus as well as against
rare latent infection in resting CD4+ T cells (Sung et al., 2015b). Here,
with the additional step of depletion of CD8 T cells prior to addition of
allogeneic target cells, we show that HIVDARTmolecule-mediated redi-
rection of effector T cells directly recognizes and clears latently infected
cells expressing HIV Env in the 24-hour period following VOR exposure.
Even at the E:T ratio of 1:10, the addition of HIV DART molecules to
CD8+ T cells led to a significant reduction in recovery of p24+ wells
(Fig. 4, p b 0.05 by Kruskal-Wallis with Dunn's post-test correction). In
comparison, CD8+ T cells alone at an E:T ratio of 1:10 were unable to
significantly reduce recovery of p24+ wells in this subset of 6
Fig. 4. Addition of HIV DARTmolecules to CD8 T cells further reduces virus recovery from
VOR exposed resting CD4 T cells. Resting CD4 T cells are exposed to 6 h of 335 nM of VOR
then co-culturedwith CD8 T cells at an E:T of 1:10, an E:T ratio selected tominimize CD8 T
cell effect, and a cocktail of HIV DARTmolecules (a 1:1mixture of 7B2xCD3 and A32xCD3)
or a control DART molecule with an irrelevant antigen specific arm in place of the HIV-
specific arm. CD8 T cells are depleted from co-culture in all systems after 24 h prior to
addition of allogeneic target cells to amplify residual virus. Results are shown as % of
plated wells p24 positive (#positive wells × 100) / (total #plated wells). *Indicates p b
0.01 by Friedman test for nonparametric paired samples with Dunn's posttest correction
for multiple comparisons.
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in Fig. 2, nor was the addition of a control DART molecule in which
the HIV-specific arm is replaced by an irrelevant arm (Fig. 4). This indi-
cates that a 6-hour exposure to VOR led to sufficient Envprotein expres-
sion on the cell surface to allow detection by an antibody-based
mechanism such as the HIV DART molecules.
As a control for the LCA, we sought to recover virus from the popu-
lation of cells that were depleted by anti-CD8+, to rule out the possibil-
ity that CD8depletionhad also removedHIV-infected cells. No viruswas
recovered from co-culture of these cell fractions. Furthermore, no
CD8+ T cells were detectable in the co-cultures by FACs analysis either
immediately followingdepletion fromco-culture, or at the conclusion of
the 2 week co-culture period with allogeneic target cells (hence not
shown).4. Discussion
The latency clearance assay was designed to provide evidence that
effectors could recognize and clear infected cells following exposure to
a latency reversal agent. An important feature of the assay is that it is
performed in an all-autologous system, using methodology (e.g. drug
concentrations, exposure times) that reflects pharmacologically rele-
vant conditions. To ensure that any reduction of virus recovery can be
attributed specifically to the activity of the immune effectors under
study, effectors are depleted from co-culture with infected cells prior
to amplification of remaining virus by co-culture in allogeneic target
cells.
Jones et al. (2016) has studied the ability of selected CD8+ T cell
clones to target latent HIV infection in a primary cell model of latency.
In this study, HIV-specific CD8+ cell clones did not recognize latently
infected cells treated with VOR. However, primary cell models are vari-
ably responsive to latency reversing agents, including VOR, when com-
pared to the responses of resting CD4+ T cells from HIV infected
individuals (Spina et al., 2013; Laird et al., 2015). Additionally, the
ex vivo exposure of VOR used in these experiments is approximately
three times higher and longer than can be achieved in vivo, and is likely
to blunt T cell function (Clutton et al., 2016).In contrast in the LCA reported here, using an all-autologous system
encompassing the use of specific participant-derived cells, we found
that VOR induced the expression of HIV to an extent sufficient to
allow clearance by ex vivo autologous CD8+ T cells, as measured by a
reduction in the recovery of virus from authentic participant-derived la-
tently infected cells. Unlike in this ex vivo study, vorinostat treatment
in vivo has not led to a detectable reduction in the size of the latent res-
ervoir (Archin et al., 2012, 2014; Elliott et al., 2014). This may be due to
the inadequacy of a single or short term in vivo vorinostat exposure to
induce antigen from a sufficient proportion of the total replication com-
petent latent reservoir to detect reductions in current assays, complex-
ities involvingmaintenance of the latent reservoir, and/or defects in the
in vivo CD8 T cell response (Deng et al., 2015). The CD8mediated clear-
ance we observed was dependent on the frequency of CD8 T cells, con-
sistent with our earlier published results using the unmodified LCA
(Sung et al., 2015a, b) as well as findings from other groups (Shan
et al., 2012; Walker-Sperling et al., 2015). This suggests that a low fre-
quency of circulatingHIV-specific effector cellsmay limit immune clear-
ance following latency reversal in vivo, but that this limitation could
potentially be overcome by interventions that increase the frequency
of HIV-specific CD8 T cells, such as HXTC therapy, or different immuno-
therapeutic approaches such as DART molecules.
The LCA as employed in this study does not directly address the pos-
sible impact of vorinostat on the CD8 T cell function, as vorinostat was
purposefully removed from culture prior to addition of CD8 T cells.
This was purposeful, as the focus of the current work is on the ability
of vorinostat to induce antigen expression, rather than evaluation of
any impact on CD8 T cell function. The potential impact of vorinostat
on CD8 T cell function has been recently addressed with multiple rigor-
ous and extensive studies. We have previously shown that vorinostat
doses reflecting achievable in vivo peakdoses and exposures did not de-
crease CD8 T cell ability to inhibit HIV virus replication, or T cell prolifer-
ation, and that supraphysiologic exposures were required to produce
any measurable impact on CD8 T cell function (Sung et al., 2015a), a
finding consistent with other groups that have examined escalated
in vitro exposures to vorinostat (Jones et al., 2016). Clutton et al.
found that exposures of vorinostat that reflect what is achievable fol-
lowing single and multiple doses (Archin et al., 2014), did not decrease
CD8 T cell function as measured by cytokine release and proliferation
(Clutton et al., 2016), and that a single dose of in vivo vorinostat had
no significant impact on CD8 T cell function either. These findings
have been replicated in studies examining multiple in vivo doses of
vorinostat (Elliott et al., 2014; Archin et al., 2017). Looking forward,
the LCA can,withminormodification, be used to evaluate a new latency
reversal agents impact on the CD8 T cell function against rare, latently
infected resting CD4 T cells.
The LCA is limited by the rare nature of latent infection in ART sup-
pressed individuals, leading to a large number of cells needing to be
assayed in each condition to obtain detectable positive signals. This
also limits the number of replicates and statistical robustness of the
data. The assay does require a substantial number of resting CD4 T
cells and is labor and time intensive. The LCA is thus not an appropriate
screening tool for LRAs, but rather is best reserved for evaluating the
most promising LRAs prior to or in parallel to clinical investigation.
It is possible that assaying a higher number of cells could have led to
a higher number of wells plated in which virus was recovered, as the
sensitivity of the assay is limited by the number of cells available.
Given available cells, 8–34 million resting CD4 T cells were assayed
per condition (Table 1), which is fewer than typically assayed to quan-
titate the frequency of latent infection QVOA (Archin et al., 2008;
Crooks et al., 2015). However, the reduction of viral recovery is uniform-
ly seen in the presence of active effectors. The use of cells directly from
ART-suppressed individuals, and the readout of replication competent
virus, increases the relevance of the data generated. As strategies are de-
veloped for clinical testing, assays such as the one presented herein will
be useful in assessing and confirming the ability of LRAs to induce levels
57J.A. Sung et al. / EBioMedicine 23 (2017) 52–58of antigen production that might be relevant for viral clearance strate-
gies. We used multiple tools and controls to interrogate the ability of
VOR to induce detectable antigen expression, with consistent results
across these approaches and conditions.
In summary, we have demonstrated that VOR is capable of inducing
HIV MHC:peptide as well as Env antigen expression on the cell surface
of latently infected, resting CD4 cells from ART suppressed individuals
at levels sufficient for clearance by a variety of effector mechanisms.
The same methods can be adapted to further understand the kinetics
of latency clearance, modeling exposures to an array of LRAs (or combi-
nation approaches) and effectormechanisms. Such effortswill be essen-
tial for the rational design of optimal combination latency reversal and
clearance strategies. Our ongoing clinical trials will attempt to validate
the LRA and clearance activities measured in the ex vivo LCA. Latency
clearance activity observed in this study suggests that HDAC inhibitors
such as VOR may prove useful when used in appropriate combination
with immune clearance strategies. Further, these findings underscore
the potential value of evaluating latency reversing agents within the
context of viral clearance ex vivo, prior to ultimate in vivo testing.
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